An underground economy for unlicensed weight-loss drugs is being driven by social media fitness personalities and sellers on messaging platforms, based on new investigations.
Experimental Treatment Gaining Popularity Online
The experimental drug, which is still in research studies, is being advertised by social media influencers for its alleged weight-reducing effects. Viewers are encouraged to message these accounts privately for source information, while also receiving promotional offers.
Thriving Trade on Social Networks
Separately, a flourishing market exists on Telegram, where communities with numerous of participants share “before and after” photos, injection guides and claims of next-day UK delivery. Sellers market the substance there before directing customers to WhatsApp for purchases.
Understanding Retatrutide
Retatrutide is an investigational injectable created by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – GLP-1, glucose-dependent insulinotropic polypeptide and glucagon. Preliminary studies suggest it could help patients reduce up to a quarter of their total weight. Referred to as the “triple G”, the drug is being promoted digitally as the successor to Ozempic.
Medical Professionals Voice Concerns
However, physicians and chemists have warned that the sale of what is still an unlicensed medication in the UK is worrisome and could result in individuals injecting products of unknown origin.
Several experts stated the popularity for the experimental drug could be linked to the increasing price of approved weight loss treatments such as Mounjaro.
Regulatory Position and Enforcement
Marketing the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved medication that cannot be marketed or distributed for human use under the British medical regulations.
Several influencers try to sidestep the regulations by referring to the substance as a “research chemical” or describing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still breach medicines, marketing, and customer laws, potentially leading to fines, prosecution or prison.
Service Response and Material Elimination
According to the social media company, the platform has taken down violative material and banned associated hashtags and search suggestions. The company stated it was committed to keeping the service secure and investing in enhancing enforcement strategies.
Online Trading Activities
Research also found groups with up to nine thousand participants marketing retatrutide using Telegram's built-in search feature, which operates like a public directory. Typing “retatrutide” instantly displays groups with thousands of users, populated with images of weight loss, positive reviews and step-by-step instructions for mixing or administering at residence.
After moments of joining one community, a seller shared WhatsApp details, where the majority of purchases occur. The seller sent an guidebook and guaranteed shipping within two days. When questioned whether the substance was genuine, one vendor said: “You can’t be sure.” Another provided a photo of a alleged testing documentation. None asked about body mass, medical conditions or past usage.
Product Details and Pricing
Inside these groups, messages show dark colored packages with postal service labels, claiming to contain fresh supplies. One message read: “It took eight of us to load them this morning.”
Buyers can choose between dry substance containers, mixed at home with sterile water, or pre-filled injectors typically sold at £160 for 20 milligrams. When asked how much time a pen should be used, sellers give contradictory responses varying between a few weeks to “depends on your body”.
Platform Moderation and Security Actions
A spokesperson for the messaging service said it regularly moderated harmful material on its platform including content that encouraged the “misuse of controlled medications”. The organization noted that it removed “millions of pieces of harmful content each day”.
Healthcare Expert Cautions
“Individuals are administering materials they cannot confirm. Even if the science behind this drug is sound, these digital products may not contain what they advertise,” said Jason Murphy, the director of pharmacy at Chemist4U.
A medical professional of Asda Online Doctor linked the increase in interest to current price rises for authorized weight-loss drugs such as Mounjaro. “With costs increasing, individuals are turning to online platforms. But counterfeit treatments are highly risky. You cannot know what’s inside or whether the conditions they were made in was clean,” she said.
Her team has previously encountered individuals injured by self-injection from unconfirmed suppliers. “We understand the disappointment, but purchasing from Telegram or communication platforms is gambling with your well-being,” stated the doctor. “These materials could be contaminated or incorrectly dosed.”
Producer Statement
A representative from Eli Lilly said the substance was in phase 3 clinical trials and had not been evaluated or authorized by any government authority anywhere in the world. “Therefore at this point no one can market [it] for human use,” they explained, adding that any product “misleadingly claiming itself as a company experimental product not yet approved … may expose patients to possibly serious health risks”.
